{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:24:58Z","timestamp":1790835898036,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,7,22]],"date-time":"2017-07-22T00:00:00Z","timestamp":1500681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1093\/jnci\/djx124","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T03:11:34Z","timestamp":1496805094000},"source":"Crossref","is-referenced-by-count":106,"title":["Neurofibromatosis Type 1\u2013Associated MPNST State of the Science: Outlining a Research Agenda for the Future"],"prefix":"10.1093","volume":"109","author":[{"given":"Karlyne M.","family":"Reilly","sequence":"first","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AeRang","family":"Kim","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri","family":"Blakely","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie E.","family":"Ferner","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Gutmann","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Legius","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku M.","family":"Miettinen","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Lor","family":"Randall","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Jumb\u00e9","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viskochil","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Affiliations of authors: Rare Tumor Initiative (KMR), Laboratory of Pathology (MMM), and Pediatric Oncology Branch (BCW), Center for Cancer Research, National Cancer Institute, Bethesda, MD; Center for Cancer and Blood Disorders, Children\u2019s National Medical Center, Washington, DC (AK); Department of Neurology, Johns Hopkins Hospital, Baltimore, MD (JB); Neurofibromatosis Center, Department of Neurology Guy's Hospital Lo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"issue":"5","key":"key\n\t\t\t\t20180730061954_djx124-B1","first-page":"1573","article-title":"International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis","volume":"62","author":"Ferner","year":"2002","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20180730061954_djx124-B2","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7429697","article-title":"Malignant peripheral nerve sheath tumors state of the science: Leveraging clinical and biological insights into effective therapies [published online ahead of print May 16, 2017]","author":"Kim","year":"2017","journal-title":"Sarcoma"},{"key":"key\n\t\t\t\t20180730061954_djx124-B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in neurofibromatosis 1 patients\u2014a consensus overview [published online ahead of print May 24, 2017]","author":"Miettinen","year":"2017","journal-title":"Hum Pathol"},{"issue":"12","key":"key\n\t\t\t\t20180730061954_djx124-B4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamapsychiatry.2016.2600","article-title":"Disease burden and symptom structure of autism in neurofibromatosis type 1: A study of the International NF1-ASD Consortium Team (INFACT)","volume":"73","author":"Morris","year":"2016","journal-title":"JAMA Psychiatry."},{"issue":"2","key":"key\n\t\t\t\t20180730061954_djx124-B5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ana.24093","article-title":"Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1","volume":"75","author":"Diggs-Andrews","year":"2014","journal-title":"Ann Neurol."},{"issue":"6","key":"key\n\t\t\t\t20180730061954_djx124-B6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: A multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol."},{"issue":"5","key":"key\n\t\t\t\t20180730061954_djx124-B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ana.24157","article-title":"Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma","volume":"75","author":"Fisher","year":"2014","journal-title":"Ann Neurol."},{"issue":"5","key":"key\n\t\t\t\t20180730061954_djx124-B8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.15252\/emmm.201404430","article-title":"Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine","volume":"7","author":"Castellsague","year":"2015","journal-title":"EMBO Mol Med."},{"issue":"9","key":"key\n\t\t\t\t20180730061954_djx124-B9","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1158\/1535-7163.MCT-11-0309","article-title":"Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells","volume":"10","author":"Wood","year":"2011","journal-title":"Mol Cancer Ther."},{"issue":"5313","key":"key\n\t\t\t\t20180730061954_djx124-B10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1126\/science.276.5313.791","article-title":"Rescue of a Drosophila NF1 mutant phenotype by protein kinase A","volume":"276","author":"The","year":"1997","journal-title":"Science."},{"key":"key\n\t\t\t\t20180730061954_djx124-B11","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04940","article-title":"Neurofibromin controls macropinocytosis and phagocytosis in Dictyostelium","volume":"4","author":"Bloomfield","year":"2015","journal-title":"Elife"},{"issue":"6","key":"key\n\t\t\t\t20180730061954_djx124-B12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1242\/dmm.009779","article-title":"Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development","volume":"5","author":"Shin","year":"2012","journal-title":"Dis Model Mech."},{"issue":"8","key":"key\n\t\t\t\t20180730061954_djx124-B13","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/onc.2016.269","article-title":"Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors","volume":"36","author":"Ki","year":"2017","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20180730061954_djx124-B14","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.9518","article-title":"Phase II trial of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumor (MPNST)","volume":"24","author":"Albritton","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"key\n\t\t\t\t20180730061954_djx124-B15","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","article-title":"Phase II study of sorafenib in patients with metastatic or recurrent sarcomas","volume":"27","author":"Maki","year":"2009","journal-title":"J Clin Oncol."},{"issue":"19","key":"key\n\t\t\t\t20180730061954_djx124-B16","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1200\/JCO.2008.20.5054","article-title":"Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model","volume":"27","author":"Chugh","year":"2009","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20180730061954_djx124-B17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.10009","article-title":"Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma","volume":"28","author":"Schuetze","year":"2010","journal-title":"J Clin Oncol."},{"issue":"10","key":"key\n\t\t\t\t20180730061954_djx124-B18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","article-title":"Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma","volume":"27","author":"Dickson","year":"2016","journal-title":"Ann Oncol."},{"key":"key\n\t\t\t\t20180730061954_djx124-B19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.11053","article-title":"SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST)","volume":"34","author":"Widemann","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20180730061954_djx124-B20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer."},{"issue":"2","key":"key\n\t\t\t\t20180730061954_djx124-B21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"13","key":"key\n\t\t\t\t20180730061954_djx124-B22","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20180730061954_djx124-B23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.10522","article-title":"SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs)","volume":"31","author":"Widemann","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/109\/8\/djx124\/25332158\/djx124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T16:04:23Z","timestamp":1602259463000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/doi\/10.1093\/jnci\/djx124\/4004723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,22]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djx124","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,8,1]]}}}